Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2010

View Archived Issues

Arena Pharma claims new prostanoid IP receptor agonists

NIH receives NIAID funding for 10 malaria research centers

Ostarine increases lean body mass and leg strength in postmenopausal women

Ortho-McNeil-Janssen describes new gamma-secretase modulators

ARYx claims novel PPAR-alpha agonists

Boehringer Ingelheim describes novel CGRP receptor antagonists

Merck & Co. characterizes new histamine H3 receptor ligands

Medivir claims novel cathepsin S inhibitors

Phase III data reveal effects of add-on dapagliflozin in poorly controlled diabetes

DegludecPlus effective in type 2 diabetes in proof-of-concept trial

First-in-human data reported on CHF-5074 for AD

Reata completes equity financing for second pivotal bardoxolone methyl trial

Ablynx licenses Nanobodies to Novartis

No difference in Levadex pharmacokinetics in smokers versus nonsmokers

NOV-002 is active in phase II trial in breast cancer

ADX-71943 shows efficacy in preclinical model of osteoarthritis pain

Neoprobe finishes CMC data review for Lymphoseek

Alexza creates Addicere Therapeutics and updates Staccato pipeline strategy

Lantheus acquires worldwide rights to gadofosveset trisodium

Ark Therapeutics provides update on key programs

Antisense Therapeutics provides update on its development pipeline

Accumetrics, Daiichi Sankyo and Lilly join to raise antiplatelet therapy awareness

Auxilium provides update on Xiaflex in Peyronie's disease

FDA warns for risk of severe liver injury in patients using Arava for RA

Intercell's Ixiaro vaccine launched in Switzerland

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...